文献速递垂体与肾上腺疾病性腺与生殖内分泌肥胖与代谢综合征

Temple综合征:60例经基因确诊的日本患者的综合临床研究

Temple Syndrome: Comprehensive Clinical Study in Genetically Confirmed 60 Japanese Patients.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该研究通过问卷收集了60例经基因确诊的Temple综合征(TS14)日本患者的详细临床资料,其中母源单亲二体14(UPD(14)mat)31例、表观突变22例、缺失5例、UPD(14)mat或表观突变2例。结果显示小于胎龄儿、出生后(约2岁)身材矮小和中枢性性早熟(CPP)分别见于88.3%、87.0%和86.0%的患者。生长激素治疗使32例患者的身高标准差评分中位数从-3.4升至-2.4,促性腺激素释放激素类似物治疗改善了32例患者的CPP。

要点

  • 小于胎龄儿、出生后身材矮小和中枢性性早熟是TS14的常见表现,分别占88.3%、87.0%和86.0%。
  • 生长激素治疗使身高标准差评分中位数从-3.4升至-2.4,促性腺激素释放激素类似物治疗改善了中枢性性早熟。
  • 多数患者的高胆固醇血症和糖尿病可通过口服药物控制,且部分在肥胖发生前即出现。

核心结论

  • 这些结果阐明了TS14的详细临床特征,并基于这些发现提出了有效的诊断方法和合适的临床管理方案。

研究设计与样本

  • 采用问卷方式向主治医师收集60例经基因确诊的TS14日本患者的详细临床资料。
  • 60例患者包括31例母源单亲二体14、22例表观突变、5例缺失和2例母源单亲二体14或表观突变。

主要发现

  • 小于胎龄儿、出生后(约2岁)身材矮小和中枢性性早熟分别见于88.3%、87.0%和86.0%的患者。
  • 32例患者接受生长激素治疗,身高标准差评分中位数从-3.4升至-2.4;32例患者接受促性腺激素释放激素类似物治疗,中枢性性早熟得到改善。
  • 智力与发育障碍见于21.6%的患者,神经发育障碍见于21.6%的患者,肥胖见于20.0%的患者。
  • 高胆固醇血症见于26.5%的6岁及以上患者,糖尿病见于12.8%的9岁及以上患者,婴儿期Silver-Russell综合征样和/或Prader-Willi综合征样表型见于87.7%的患者。
  • 42.9%的患者在儿童期就读于特殊班级,而98.2%的患者在成年期上大学或就业;相当一部分TS14患者在高胆固醇血症和糖尿病在肥胖发生前即被观察到,且大多数受影响患者通过口服药物得到控制。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Temple syndrome (TS14) is a rare 14q32.2-related imprinting disorder. Here we report comprehensive clinical findings in TS14. METHODS: We obtained detailed clinical findings in 60 Japanese patients with genetically confirmed TS14, using a questionnaire to attending physicians. The 60 patients consisted of 31 with maternal uniparental disomy 14 [UPD(14)mat], 22 with epimutation, 5 with deletions, and 2 with UPD(14)mat or epimutation. RESULTS: Small for gestational age, postnatal (∼2 years of age) short stature, and central precocious puberty (CPP) were identified in 88.3%, 87.0%, and 86.0% of patients, respectively. GH therapy was performed in 32 patients, increasing the median height SD score for height from -3.4 to -2.4, and GnRH analog therapy was performed in 32 patients, ameliorating CPP. Furthermore, the survey showed intellectual and developmental disabilities in 21.6% of patients, neurodevelopmental disorders in 21.6% of patients, obesity in 20.0% of patients, hypercholesterolemia in 26.5% of patients aged ≥6 years, diabetes mellitus in 12.8% of patients aged ≥9 years, and Silver-Russell syndrome-like and/or Prader-Will syndrome-like phenotypes in 87.7% of patients in infancy. Notably, 42.9% of patients were enrolled in special classes in childhood, whereas 98.2% of patients attended college or had jobs in adulthood. Hypercholesterolemia and diabetes mellitus were observed before the development of obesity in a substantial fraction of TS14 patients and were controlled by oral medications in most affected patients. CONCLUSION: These results clarify the detailed clinical characteristics of TS14. On the basis of these findings, we propose an efficient diagnostic approach and pertinent clinical management for TS14 patients.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ogawa T, Narusawa H, Nagasaki K, et al. Temple Syndrome: Comprehensive Clinical Study in Genetically Confirmed 60 Japanese Patients. J Clin Endocrinol Metab. 2025. PMID: 39693239. doi:10.1210/clinem/dgae883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。